A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors
Latest Information Update: 26 Jun 2025
At a glance
- Drugs ALN-HSD (Primary)
- Indications Fibrosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms NASHGEN-2
- Sponsors Regeneron Pharmaceuticals
Most Recent Events
- 18 Apr 2025 Planned number of patients changed from 120 to 90.
- 05 Apr 2024 Status changed from active, no longer recruiting to recruiting.
- 13 Feb 2024 The protocol has been amended to reduce the number of arms from roughly six to two while keeping the other study parameters unchanged and research will be done in one part.